With a market capitalization (market cap) of $2.93B — a measure of how much the company is worth — Vericel Corporation ranks #1,715 among the 2,422 companies tracked, and 215th in Healthcare as of November 16, 2026. Shares trade at $57.48, up 0.91% on the day.
As of November 16, 2026 · Prices may be delayed
of 2,422 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 9, 2026. The headline market cap is from the ranking update on November 16, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 9, 2026 | $2.99B | +63.47% | $58.39 |
| 2025 | Dec 31, 2025 | $1.83B | -33.28% | $36.01 |
| 2024 | Dec 31, 2024 | $2.74B | +61.17% | $54.91 |
| 2023 | Dec 29, 2023 | $1.7B | +36.66% | $35.61 |
Ranking figure $2.93B as of November 16, 2026.
Market cap = share price × shares outstanding.
Vericel Corporation's ranking market cap is the reported market cap from the latest ranking update, with a share price of $57.48 as of November 16, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $2.99B on November 9, 2026. See how the ranking works.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 50,591,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
Latest price ÷ annual earnings per share
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $57.48.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.35T | -0.64% |
| #20 | Johnson & Johnson JNJ | $680.19B | -1.12% |
| #23 |
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 16, 2026, Vericel Corporation (VCEL) is worth $2.93B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Vericel Corporation’s book equity is about $354.64M. Market cap is the market value of the outstanding shares. As of November 16, 2026, its market cap is $2.93B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Vericel Corporation ranks #1,715 among the 2,422 companies tracked on MarketCapLens. In Healthcare it ranks #215 of 353.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
| 2022 | Dec 30, 2022 | $1.24B | -32.62% | $26.34 |
|---|
| 2021 | Dec 31, 2021 | $1.85B | — | $39.30 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
FY 2025
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $520.86B |
| -0.12% |
| #30 | UnitedHealth Group Incorporated UNH | $369.18B | +1.12% |
| #32 | Merck & Co., Inc. MRK | $356.13B | -2.23% |
| #37 | Novartis AG NVS | $302.56B | -0.19% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1712 | Liberty Latin America Ltd. LILA | $2.94B | +1.42% |
| #1713 | Disc Medicine, Inc. IRON | $2.94B | -4.26% |
| #1714 | IDEAYA Biosciences, Inc. IDYA | $2.94B | -4.62% |
| #1716 | Constellium SE CSTM | $2.93B | -2.55% |
| #1717 | Archer Aviation Inc. ACHR | $2.93B | -7.20% |
| #1718 | Versigent PLC VGNT | $2.91B | -2.49% |
Vericel Corporation’s ranking market cap of $2.93B comes from the same snapshot as the rest of this site, as of November 16, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 50,591,000. The historical market-cap series last observed $2.99B on November 9, 2026.
Over the past year, Vericel Corporation’s market cap is up 51.52%, using historical market-cap records rather than today’s share count applied to past prices.
Vericel Corporation (VCEL) shares trade at $57.48, up 0.91% on the day, as of November 16, 2026.
Vericel Corporation trades at a live price-to-earnings (P/E) ratio of 174.2, using the latest share price divided by the latest annual earnings per share. That is not the same as a fiscal-year reported P/E.